Burak Yasin Aktaş

机构：Cancer Institute (WIA), Hacettepe University Hospital, Aselsan (Turkey), Hacettepe University · ORCID：0000-0001-5460-4895

发表论文 118 篇 · 总被引 362 次 · h-index 11

代表论文

First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE). (2024 · Journal of Clinical Oncology · 被引 6)
Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel (2025 · Medicina · 被引 5)
The predictive role of PD-L1 expression and CD8 + TIL levels in determining the neoadjuvant chemotherapy response in advanced ovarian cancer (2024 · Journal of Ovarian Research · 被引 4)
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer (2024 · BMC Cancer · 被引 2)
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial. (2024 · Journal of Clinical Oncology · 被引 2)
Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study (2025 · Discover Oncology · 被引 1)